CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
To read the full story
Related Article
- Chuikyo OKs 2022 Reform Outline for Cost-Effectiveness Assessment System
December 2, 2021
- Pharma Calls for Enhancing Pre-Analysis Discussions in CEA Scheme: Chuikyo
November 15, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- Chuikyo Raises No Objections to MHLW Proposal on Revision of CEA Analysis Process
September 17, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- Chuikyo Roughly Approves 11 Proposals to Hone CEA System
July 26, 2021
- Japan’s First CEA-Based Price Tweaks Draw Near, April Listing Round at Earliest
February 9, 2021
COMMENTARY
- Taking on Solid Tumors - 9: ADCs Surge Ahead as TCEs Strive for a Foothold
July 18, 2025
- FY2024 Sees Divergence in I/O Drug Sales, Keytruda Thrives while Rivals Face Pricing Headwinds
July 4, 2025
- Honebuto 2025 Approved - The Real Battle for Pharma Lies Ahead
June 23, 2025
- Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
May 27, 2025
- Impact of US Drug Policy: President Trump Shaking the World of Pharma
May 19, 2025
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…